Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

• Status: Completed
• Trial end date: 2017-01-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effective dose(s) of RPC4046 in the treatment of Eosinophilic Esophagitis (EoE). This trial consists of two phases: 16 weeks of double-blind treatment and 52 weeks of open-label extension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celgene

Criteria

Inclusion Criteria:

• Histologic evidence of EoE

• Clinical symptoms of EoE including dysphagia

Exclusion Criteria:

• Primary causes of esophageal eosinophilia other than EoE